Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Operating Expenses (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Operating Expenses for 10 consecutive years, with $320.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 11.71% to $320.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 billion, a 10.22% increase, with the full-year FY2025 number at $1.2 billion, up 10.22% from a year prior.
  • Operating Expenses was $320.6 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $330.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $330.8 million in Q3 2025 to a low of $169.8 million in Q2 2021.
  • A 5-year average of $252.6 million and a median of $255.4 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 84.15% in 2022, then dropped 23.0% in 2023.
  • Ultragenyx Pharmaceutical's Operating Expenses stood at $186.0 million in 2021, then soared by 33.89% to $249.0 million in 2022, then grew by 0.0% to $249.0 million in 2023, then rose by 15.25% to $287.0 million in 2024, then grew by 11.71% to $320.6 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Operating Expenses are $320.6 million (Q4 2025), $330.8 million (Q3 2025), and $274.4 million (Q2 2025).